[1]魏 炜.奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较[J].医学信息,2021,34(14):160-162.[doi:10.3969/j.issn.1006-1959.2021.14.045]
　WEI Wei.Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension[J].Medical Information,2021,34(14):160-162.[doi:10.3969/j.issn.1006-1959.2021.14.045]
点击复制

奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年14期
页码:
160-162
栏目:
药物与临床
出版日期:
2021-07-15

文章信息/Info

Title:
Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension
文章编号:
1006-1959（2021）14-0160-03
作者:
魏 炜
（天津市滨海新区塘沽大华医院全科，天津 300455）
Author(s):
WEI Wei
(General Department,Tanggu Dahua Hospital,Binhai New District,Tianjin 300455,China)
关键词:
原发性高血压; 血压平滑指数; 血压变异性; 奥美沙坦酯; 坎地沙坦酯
Keywords:
Essential hypertension; Blood pressure smoothing index; Blood pressure variability;  Olmesartan medoxomil; Candesartan cilexetil
分类号:
R972；R544.1
DOI:
10.3969/j.issn.1006-1959.2021.14.045
文献标志码:
A
摘要:
目的 观察奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果并比较。方法 选取我院2019年1月~2020年12月进行治疗的90例原发性高血压为研究对象，按照随机数字法为对照组与研究组，每组45例。对照组采用坎地沙坦酯治疗，研究组服用奥美沙坦酯治疗。比较两组治疗前后的的血压、心率、心电图和血、尿常规、动态血压、血压平滑指数（SI）及疗效。结果 治疗后两组血压低于治疗前，研究组低于对照组，差异有统计学意义（P＜0.05）；治疗后两组收缩压平滑指数（SISBP）、舒张压平滑指数（SIDBP）均高于治疗前，差异有统计学意义（P＜0.05），组间比较，差异无统计学意义（P＞0.05）；研究组治疗总有效率为84.44%，与对照组的80.00%比较，差异无统计学意义（P＞0.05）。结论 奥美沙坦酯和坎地沙坦酯治疗原发性高血压疗效相当，但奥美沙坦酯SI更高，血压变异性更低。
Abstract:
Objective To observe and compare the effects of olmesartan medoxomil and candesartan medoxomil in the treatment of essential hypertension.Methods A total of 90 cases of essential hypertension who were treated in our hospital from January 2019 to December 2020 were selected as the research objects, and the control group (n=45) and the study group (n=45) were selected according to the random number method.The control group was treated with candesartan cilexetil and the study group was treated with olmesartan medoxomil.The blood pressure, heart rate, electrocardiogram, blood, urine routine, ambulatory blood pressure, blood pressure smoothing index (SI) and curative effect of the two groups before and after treatment were compared.Results After treatment, the blood pressure of the two groups was lower than before treatment, and the study group was lower than the control group, the difference was statistically significant (P＜0.05);After treatment, the systolic blood pressure smoothing index (SISBP) and diastolic blood pressure smoothing index (SIDBP) were higher than before treatment,the difference was statistically significant (P＜0.05).There was no statistically significant difference between the groups (P＞0.05);The total effective rate of treatment in the study group was 84.44%, compared with 80.00% in the control group, the difference was not statistically significant (P＞0.05).Conclusion Olmesartan medoxomil and candesartan cilexetil have equivalent efficacy in the treatment of essential hypertension, but olmesartan medoxomil has a higher SI and lower blood pressure variability.

参考文献/References:

[1]东珍.高血压合并2型糖尿病患者不同治疗方案的疗效观察[J].中国预防医学杂志,2018,33(21):342-344. [2]席婷,姬学光,周静,等.阿利沙坦酯片治疗原发性高血压患者颈动脉硬化病变的疗效[J].心血管康复医学杂志,2019,28(1):46-51. [3]邢钰,吕业,刘宇宙,等.珍菊降压片联合坎地沙坦酯治疗高血压的临床研究[J].现代药物与临床,2019,34(4):1012-1015. [4]《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治,2019,19(1):1-44. [5]孔德玲,史孝玲.阿托伐他汀钙联合降压药物对高血压患者动态血压及脉压指数和降压平稳性的影响[J].中华实用诊断与治疗杂志,2015,29(11):1138-1140. [6]汪庆飞,高家荣,张配.坎地沙坦酯联合氢氯噻嗪治疗中重度高血压的临床疗效比较[J].中华全科医学,2019,17(7):69-71. [7]高菲.国产奥美沙坦酯治疗原发性高血压的疗效及其对血压变异性的影响[J].心血管康复医学杂志,2019,28(1):79-83. [8]李楠,郑关毅.高血压颈动脉粥样硬化痰瘀证与脑梗死的关系[J].福建医科大学学报,2020,54(5):36-40,75. [9]包恩泽,李贵华,皮林,等.联合降压药物方案治疗老年原发性高血压疗效及作用机制研究[J].临床军医杂志,2019,47(3):231-233. [10]王改玲.坎地沙坦联合氟哌噻吨美利曲辛片治疗原发性高血压伴情绪异常的疗效观察[J].中西医结合心脑血管病杂志,2018,16(13):1856-1858. [11]管晶晶.心可舒片联合缬沙坦治疗原发性高血压的临床研究[J].现代药物与临床,2019,34(9):2622-2626. [12]郭书英,吴传亮,刘卫,等.缬沙坦氨氯地平联合治疗原发性高血压的临床有效性和安全性[J].解放军药学学报,2018,34(5):73-74,92. [13]郭建新.奥美沙坦对原发性高血压病人血清脂联素、内皮细胞分化功能和颈动脉粥样硬化的影响[J].中西医结合心脑血管病杂志,2018,16(20):3027-3029. [14]谢静,闵青.奥美沙坦酯与氨氯地平联合氢氯噻嗪治疗高血压的临床研究[J].药物评价研究,2020,43(9):162-165. [15]权中文.苯磺酸左旋氨氯地平片治疗原发性高血压的效果研究[J].山西医药杂志,2020,49(21):71-72. [16]宋莉,颜红兵,赵汉军,等.赖诺普利氢氯噻嗪片治疗轻中度原发性高血压的疗效和安全性的多中心观察性临床研究[J].中国心血管杂志,2019,24(1):63-67. [17]杨义,杨缙,彭艳.有氧运动联合药物治疗对原发性高血压的疗效及对炎性因子的影响[J].基因组学与应用生物学,2018,37(11):146-151. [18]高霞,苗迎春,李子富,等.阿司匹林联合厄贝沙坦治疗原发性高血压合并冠心病疗效及对患者凝血功能影响[J].陕西医学杂志,2018,47(10):1337-1339.

相似文献/References:

[1]段淑婷,王义围,王兆鹏.高血压病合并糖调节受损患者血压变异性的相关研究[J].医学信息,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
　DUAN Shu-ting,WANG Yi-wei,WANG Zhao-peng.Study on Blood Pressure Variability in Patients with Hypertension Complicated with Impaired Glucose Regulation[J].Medical Information,2018,31(14):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
[2]张 伟.动态血压监测不同剂型硝苯地平在原发性高血压患者中的治疗效果[J].医学信息,2022,35(10):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
　ZHANG Wei.Effect of Different Dosage Forms of Nifedipine on Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension[J].Medical Information,2022,35(14):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
[3]李信明,刘春梅,任正强,等.供需平衡视角下原发性高血压的病机与防治[J].医学信息,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
　LI Xin-Ming,LIU Chun-Mei,REN Zheng-Qiang,et al.Pathogenesis and Prevention of Essential Hypertension from the Perspective of Supply and Demand Balance[J].Medical Information,2018,31(14):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
[4]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
　MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Medical Information,2019,32(14):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
[5]熊依良.奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析[J].医学信息,2018,31(19):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
　XIONG Yi-liang.Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension[J].Medical Information,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
[6]郑艳芳,郭军霞,张永春.原发性高血压合并阵发性心房颤动的危险因素分析[J].医学信息,2021,34(22):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
　ZHENG Yan-fang,GUO Jun-xia,ZHANG Yong-chun.Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2021,34(14):51.[doi:10.3969/j.issn.1006-1959.2021.22.014]
[7]潘建鑫.高血压患者血小板/淋巴细胞比值与颈动脉粥样硬化的相关性分析[J].医学信息,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
　Pan Jianxin.Correlation analysis of platelet/lymphocyte ratio and carotid atherosclerosisin patients with primary hypertension[J].Medical Information,2020,33(14):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
[8]谢祥红.AngⅡ、ET-1对高血压患者病情发生发展的影响[J].医学信息,2020,33(16):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
　XIE Xiang-hong.Effects of AngⅡ and ET-1 on the Occurrence and Development of Hypertension Patients[J].Medical Information,2020,33(14):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
[9]刘 柳,吕风华.原发性高血压患者脉压与左心室肥厚及射血分数保留的心衰的相关性[J].医学信息,2021,34(01):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
　LIU Liu,LYU Feng-hua.Correlation of Pulse Pressure with Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction in Patients with Essential Hypertension[J].Medical Information,2021,34(14):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
[10]谭碧峰,黄友良,凌 莎,等.基于有序Logistic回归模型的H型高血压疗效影响因素研究[J].医学信息,2022,35(05):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
　TAN Bi-feng,HUANG You-liang,LING Sha,et al.Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model[J].Medical Information,2022,35(14):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]

更新日期/Last Update: 1900-01-01